Immune Thrombocytopenia (ITP) Market Research Report - Forecast till 2027

Global Immune Thrombocytopenia (ITP) Market: By Treatment (Intravenous immunoglobulins, Corticosteroids, Thrombopoietin receptor agonists, Others), By End-user (Hospitals and clinics, Specialty Centers, Research and Academic Institutes, others) — Forecast till 2027

ID: MRFR/Pharma/5531-CR | December 2018 | Region: Global | 105 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Snapshot:


The Global Market for Immune Thrombocytopenia is projected to surpass a valuation of USD 2,300 Mn by 2023, reflecting a compound annual growth rate of 5.78% between 2018 and 2023. Rising prevalence of immune thrombocytopenia (ITP) worldwide has fueled the demand for ITP therapeutics. Increased government effort to improve healthcare infrastructure in countries such as India, China and Brazil has reflected favorably on the global ITP market. In addition, increased focus on development of novel drugs and therapeutics is also having a positive impact on the market. Autoimmune diseases, chronic infections, medications, pregnancy, and certain cancers are common secondary triggers of ITP.


Synopsis:


The MRFR report includes a thorough assessment of the global immune thrombocytopenia (ITP) market along with a five-year (2018-2023) revenue forecast. The report includes a discussion on several key market elements. The scope of the discussion also covers different ITP treatments that are currently available such as intravenous immunoglobulins, thrombopoietin receptor agonists and corticosteroids among other. It also covers revenue analysis of major end-users of immune thrombocytopenia, which covers hospitals and clinics, specialty centers, and research and academic institutes.  A detail analysis of the various sub-markets across key region of the world is also available in the report.


Report Coverage:


Historical market trends, market dynamics, forecast, market value by region as well as by segmentation, country-level analysis for each market segment, key player’s market share analysis and market factor analysis which covers supply chain and Porter’s five forces analysis of the market


Companies Covered:


CSL Limited, Amgen Inc., F.Hoffmann-La Roche Ltd., Kyowa Hakko Kirin Co., Ltd., Rigel Pharmaceuticals, Inc., Shionogi Inc., Dova Pharmaceuticals, Novartis AG, Jiangsu Hengrui Pharmaceutical Co., Ltd., Shire and Ligand Pharmaceuticals, Inc.


Research Methodology:


The research methodology envelops the range and depth of markets and industries that ensures the best outlooks are presented. The methodology successfully combines primary and secondary research methods to present exclusive and pertinent content that can aid in well-versed decision making. The different advances in markets are uniquely included in the reports by employing top-down and bottom-up approaches. Insightful data, advantageous scenarios, and outline of the emerging markets make for a complete and astute guide into the beat of the market. Also, the consistency levels of our reports offer our users adept intelligence that can shape the base of strategies they devise to gain the preferred market portions and hold & enhance their current customer base in several geographies.   


Other Description:



  • Market Denomination- USD Mn

  • Base Year- 2017

  • Forecast Period- from 2018 to 2023


For the scope of the research, MRFR’s report offers a comprehensive segmental analysis of the global market for immune thrombocytopenia (ITP)


By Treatment:



  • Intravenous immunoglobulins

  • Corticosteroids

  • Thrombopoietin receptor agonists

  • Others


By End-user:



  • Hospitals and clinics

  • Specialty centers

  • Research and academic institutes

  • Others


By Region:



  • Americas

  • Europe

  • Asia Pacific (APAC)

  • The Middle East & Africa (MEA)



Frequently Asked Questions (FAQ) :


Immune thrombocytopenia (ITP) market is projected to grow at a 5.78% CAGR between 2020-2027.

Immune thrombocytopenia (ITP) market is predicted to touch USD 2,300 million by 2023.

The Americas is expected to lead the immune thrombocytopenia (ITP) market.

Rising prevalence of ITP and focus on developing new drugs are the key factors driving the immune thrombocytopenia (ITP) market.

Risk of side effects may limit the immune thrombocytopenia (ITP) market.

Immune Thrombocytopenia (ITP) is best defined as the disorder of improper clotting of blood. ITP usually causes extensive bruising and bleeding due to the severe drop in platelets counts or thrombocytes in the blood. The market is expected to witness an above-average CAGR of 5.78% from 2018 to 2023 and reach a valuation of USD 2,361.2 Mn. ITP can occur in both adults and minors.  ITP can be classified as primary, i.e., occurring on its own, or secondary, occurring alongside another condition. Autoimmune diseases, medications, chronic infections, pregnancy and certain type of cancers are common secondary triggers of ITP. The condition is one of the most common bleeding disorders identified amongst healthy minors between the age group of2 and 10 years. Over the years, the prevalence rate of ITP has increased to a significant level, which is fueling the demand for ITP treatments.


Some of the ITP treatment options that are commonly opted for include thrombopoietin receptor agonists, immune-suppressing drugs, intravenous   immune   globulin (IVIG) and corticosteroids. Among these, thrombopoietin receptor agonists is a relatively more popular treatment option. These treatments are accepted by most governing bodies in the global healthcare sectors. However, no treatment module ensure completes success and involves moderate risk of side-effects. In worse scenarios, the treatment may possibly trigger dizziness, headache, nausea, vomiting, or add further complications.


Segmental Analysis:


The segmental analysis of the global ITP market is based on type, treatment, end-user and region. By type, the market has been segmented into chronic immune thrombocytopenia and acute immune thrombocytopenia. In 2017, the chronic immune thrombocytopenia segment for 85% share of the global market. During the forecast period, the segment is projected to witness a CAGR of 5.94% and reach a valuation of USD 2,036.9 Mn. This can be attributed to factors such as rising incidence rates, approval of targeted treatments, increase in risk factors, use of prior medications, and increase occurrence of secondary hematological disorders.


On the basis of the treatment, the market has been segmented into intravenous immunoglobulins, corticosteroids, thrombopoietin receptor agonists, and others.  In 2017, the corticosteroids segmented represented 40% share of the global ITP market in terms of value. The segment is likely to surge at a CAGR of 5.57% during the assessment period. Corticosteroids are a class of steroid hormones that are commonly used in ITP therapies.


On the basis of end-user, the market has been segmented into hospitals and clinics, specialty centers, research and academic institutes, and others. The hospitals & clinic segment currently commands for close to 38% market share and is projected to capture an impressive CAGR of 6.22% during the review period.


Regional Outlook:  


On the basis of region, the Global ITP market is segmented into Americas, Europe, Asia Pacific (APAC) and the Middle East & Africa (MEA). Of these, the Americas accounted for 43.3% market share in 2017. The Americas is expected to spearhead the global ITP market throughout the assessment period. This is primarily owing to the increasing prevalence rates coupled with the availability of treatment options and presence effective reimbursement policies. According to the National Organization for Rare Disorders (NORD), the prevalence of immune thrombocytopenia among adults in the US is estimated to be 3.3 per 100,000 adults/year. In addition, Americas is expected to remain an important market for ITP during the assessment period. Americas is followed by Europe and Asia-Pacific respectively. In Europe, factors such as favorable government policies and high healthcare expenditure is supporting the growth of the market. At the same time, presence of advanced healthcare infrastructure is providing an impetus to the market in Europe. The region is likely to remain its second spot over 2023. In Asia Pacific, increased efforts towards improving healthcare services and rising level of awareness among people is anticipated to drive the market’s growth in APAC in the forthcoming years.


Competition Tracking:


Notable players operating in the Global Immune Thrombocytopenia (ITP) Market include Amgen Inc., CSL Limited, Dova Pharmaceuticals, F.Hoffmann-La Roche Ltd., Jiangsu Hengrui Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Ligand Pharmaceuticals, Inc., Novartis AG, Rigel Pharmaceuticals, Inc., Shire, and Shionogi Inc.

1 Report Prologue

2 Executive Summary

3 Introduction

3.1 Definition 18

3.2 Scope of the Study 18

3.3 List of Assumptions 19

3.4 Market Structure 19

4 Research Methodology

4.1 Research Process 21

4.2 Primary Research 22

4.3 Secondary Research 23

4.4 Market Size Estimation 23

4.5 Forecast Model 24

5 Market Dynamics

5.1 Overview 26

5.2 Drivers 27

5.2.1 Rising prevalence of Immune Thrombocytopenia (ITP) 27

5.2.2 Growing financial support by various private and government organizations 27

5.3 Restraints 27

5.3.1 Side effects of treatment options 27

5.3.2 High cost of IVIG treatment 28

5.4 Opportunities 28

5.4.1 Emerging therapies in immune thrombocytopenia 28

6 Market Factor Analysis

6.1 Value chain analysis 30

6.1.1 R&D and Designing 30

6.1.2 Manufacturing 30

6.1.3 Distribution & Sales 30

6.1.4 Post-Sales Monitoring 30

6.2 Porter’s Five Forces Model 31

6.2.1 Bargaining Power of Suppliers 32

6.2.2 Bargaining Power of Buyers 32

6.2.3 Threat of New Entrants 32

6.2.4 Threat of Substitutes 32

6.2.5 Intense Rivalry 32

7 Global Immune Thrombocytopenia (ITP) Market by Type

7.1 Overview 34

7.2 Acute Immune Thrombocytopenia 35

7.3 Chronic Immune Thrombocytopenia 35

8 Global Immune Thrombocytopenia (ITP) Market by Treatment

8.1 Overview 37

8.2 Corticosteroids 38

8.3 Thrombopoietin receptor agonists 38

8.4 Intravenous Immunoglobulins (IVIG) 39

9 Global Immune Thrombocytopenia (ITP) Market by End-user

9.1 Overview 41

9.2 Hospital & Clinics 42

9.3 Specialty Centers 42

9.4 Research and Academic Institutes 43

10 Global Immune Thrombocytopenia (ITP) Market by Region

10.1 Overview 45

10.2 Americas 47

10.2.1 North America 48

10.2.1.1 US 50

10.2.1.2 Canada 51

10.2.2 South America 52

10.3 Europe 54

10.3.1 Western Europe 55

10.3.1.1 Germany 57

10.3.1.2 France 58

10.3.1.3 UK 59

10.3.1.4 Italy 60

10.3.1.5 Spain 61

10.3.1.6 Rest of Western Europe 62

10.3.2 Eastern Europe 63

10.4 Asia-Pacific 65

10.4.1 Japan 66

10.4.2 China 67

10.4.3 India 68

10.4.4 South Korea 69

10.4.5 Australia 71

10.4.6 Rest of Asia-Pacific 72

10.5 Middle East & Africa 73

10.5.1 Middle East 74

10.5.2 Africa 75

11 Competitive Landscape

11.1 Overview 78

11.2 Company Share Analysis 78

12 Company Profiles

12.1 Amgen Inc. 80

12.1.1 Company Overview 80

12.1.2 Financial Overview 80

12.1.3 Products/Services Offered 81

12.1.4 Key Developments 81

12.1.5 SWOT Analysis 81

12.1.6 Key Strategy 81

12.2 CSL Limited 82

12.2.1 Financial Overview 82

12.2.2 Products/Services Offered 82

12.2.3 Key Developments 82

12.2.4 SWOT Analysis 83

12.2.5 Key Strategy 83

12.3 Dova Pharmaceuticals 84

12.3.1 Company Overview 84

12.3.2 Financial Overview 84

12.3.3 Products/Services Offered 84

12.3.4 Key Developments 84

12.3.5 SWOT Analysis 85

12.3.6 Key Strategy 85

12.4 F. Hoffmann-La Roche Ltd 86

12.4.1 Company Overview 86

12.4.2 Financial Overview 86

12.4.3 Products/Services Offered 86

12.4.4 Key Developments 87

12.4.5 SWOT Analysis 87

12.4.6 Key Strategy 87

12.5 Jiangsu Hengrui Pharmaceutical Co., Ltd. 88

12.5.1 Company Overview 88

12.5.2 Financial Overview 88

12.5.3 Products/Services Offered 88

12.5.4 SWOT Analysis 88

12.5.5 Key Developments 89

12.5.6 Key strategy 89

12.6 Kyowa Hakko Kirin Co., Ltd. 90

12.6.1 Company Overview 90

12.6.2 Financial Overview 90

12.6.3 Products/Services Offered 91

12.6.4 Key Developments 91

12.6.5 SWOT Analysis 91

12.6.6 Key Strategy 91

12.7 Ligand Pharmaceuticals, Inc. 92

12.7.1 Company Overview 92

12.7.2 Financial Overview 92

12.7.3 Products/Services Offered 92

12.7.4 Key Developments 93

12.7.5 SWOT Analysis 93

12.7.6 Key Strategy 93

12.8 Novartis AG 94

12.8.1 Company Overview 94

12.8.2 Financial Overview 94

12.8.3 Products/Services Offered 94

12.8.4 Key Developments 95

12.8.5 SWOT Analysis 95

12.8.6 Key Strategy 95

12.9 Rigel Pharmaceuticals, Inc. 96

12.9.1 Company Overview 96

12.9.2 Financial Overview 96

12.9.3 Products/Services Offered 96

12.9.4 Key Developments 97

12.9.5 SWOT Analysis 97

12.9.6 Key Strategy 97

12.10 Shire 98

12.10.1 Company Overview 98

12.10.2 Financial Overview 98

12.10.3 Products/Services Offered 99

12.10.4 Key Developments 99

12.10.5 SWOT Analysis 99

12.10.6 Key Strategy 99

12.11 Shionogi Inc. 100

12.11.1 Company Overview 100

12.11.2 Financial Overview 100

12.11.3 Products/Services Offered 101

12.11.4 Key Developments 101

12.11.5 SWOT Analysis 101

12.11.6 Key Strategy 101

13 Appendix

13.1 Discussion Blue Print 103

14 List of Tables

TABLE 1 MARKET SYNOPSIS 16

TABLE 2 LIST OF ASSUMPTIONS 19

TABLE 3 PRIMARY INTERVIEWS 21

TABLE 4 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 34

TABLE 5 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR ACUTE ITP BY REGION, 2020 TO 2027 (USD MILLION) 35

TABLE 6 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR CHRONIC ITP BY REGION, 2020 TO 2027 (USD MILLION) 35

TABLE 7 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 38

TABLE 8 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR CORTICOSTEROIDS BY REGION, 2020 TO 2027 (USD MILLION) 38

TABLE 9 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR THROMBOPOIETIN RECEPTOR AGONISTS BY REGION, 2020 TO 2027

(USD MILLION) 38

TABLE 10 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR INTRAVENOUS IMMUNOGLOBULINS (IVIG) BY REGION, 2020 TO 2027 (USD MILLION) 39

TABLE 11 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 41

TABLE 12 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR HOSPITAL & CLINICS BY REGION, 2020 TO 2027 (USD MILLION) 42

TABLE 13 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR SPECIALTY CENTERS BY REGION, 2020 TO 2027 (USD MILLION) 42

TABLE 14 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET FOR RESEARCH AND ACADEMIC INSTITUTES BY REGION, 2020 TO 2027

(USD MILLION) 43

TABLE 15 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2020 TO 2027 (USD MILLION) 46

TABLE 16 AMERICAS IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2020 TO 2027 (USD MILLION) 47

TABLE 17 AMERICAS IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 47

TABLE 18 AMERICAS IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 48

TABLE 19 AMERICAS IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 48

TABLE 20 NORTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY COUNTRY, 2020 TO 2027 (USD MILLION) 49

TABLE 21 NORTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 49

TABLE 22 NORTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 49

TABLE 23 NORTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 50

TABLE 24 US IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 50

TABLE 25 US IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 50

TABLE 26 US IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 51

TABLE 27 CANADA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 51

TABLE 28 CANADA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 51

TABLE 29 CANADA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 52

TABLE 30 SOUTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 52

TABLE 31 SOUTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 52

TABLE 32 SOUTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 53

TABLE 33 EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2020 TO 2027 (USD MILLION) 54

TABLE 34 EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 54

TABLE 35 EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 55

TABLE 36 EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 55

TABLE 37 WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY COUNTRY, 2020 TO 2027 (USD MILLION) 56

TABLE 38 WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 56

TABLE 39 WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 56

TABLE 40 WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 57

TABLE 41 GERMANY IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 57

TABLE 42 GERMANY IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 57

TABLE 43 GERMANY IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 58

TABLE 44 FRANCE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 58

TABLE 45 FRANCE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 58

TABLE 46 FRANCE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 59

TABLE 47 UK IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 59

TABLE 48 UK IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 59

TABLE 49 UK IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 60

TABLE 50 ITALY IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 60

TABLE 51 ITALY IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 60

TABLE 52 ITALY IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 61

TABLE 53 SPAIN IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 61

TABLE 54 SPAIN IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 61

TABLE 55 SPAIN IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 62

TABLE 56 REST OF WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 62

TABLE 57 REST OF WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 62

TABLE 58 REST OF WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 63

TABLE 59 EASTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 63

TABLE 60 EASTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 63

TABLE 61 EASTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 64

TABLE 62 ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY COUNTRY, 2020 TO 2027 (USD MILLION) 65

TABLE 63 ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 65

TABLE 64 ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 66

TABLE 65 ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 66

TABLE 66 JAPAN IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 66

TABLE 67 JAPAN IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 67

TABLE 68 JAPAN IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 67

TABLE 69 CHINA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 67

TABLE 70 CHINA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 68

TABLE 71 CHINA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 68

TABLE 72 INDIA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 68

TABLE 73 INDIA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 69

TABLE 74 INDIA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 69

TABLE 75 SOUTH KOREA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 69

TABLE 76 SOUTH KOREA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 70

TABLE 77 SOUTH KOREA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 70

TABLE 78 AUSTRALIA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 71

TABLE 79 AUSTRALIA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 71

TABLE 80 AUSTRALIA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 71

TABLE 81 REST OF ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 72

TABLE 82 REST OF ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 72

TABLE 83 REST OF ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 72

TABLE 84 MIDDLE EAST & AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2020 TO 2027 (USD MILLION) 73

TABLE 85 MIDDLE EAST & AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 73

TABLE 86 MIDDLE EAST & AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 74

TABLE 87 MIDDLE EAST & AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 74

TABLE 88 MIDDLE EAST IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 74

TABLE 89 MIDDLE EAST IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 75

TABLE 90 MIDDLE EAST IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 75

TABLE 91 AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 75

TABLE 92 AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 TO 2027 (USD MILLION) 76

TABLE 93 AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 76


15 List of Figures

FIGURE 1 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET: MARKET STRUCTURE 19

FIGURE 2 RESEARCH PROCESS 21

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 24

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET 26

FIGURE 5 VALUE CHAIN: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET 30

FIGURE 6 PORTER’S FIVE FORCES ANALYSIS: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET 31

FIGURE 7 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TYPE, 2020 & 2027 (USD MILLION) 34

FIGURE 8 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY TREATMENT, 2020 & 2027 (USD MILLION) 37

FIGURE 9 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY END-USER, 2020 & 2027 (USD MILLION) 41

FIGURE 10 GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2020 & 2027 (USD MILLION) 46

FIGURE 11 AMERICAS IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2020 (%) 47

FIGURE 12 NORTH AMERICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY COUNTRY, 2020 (%) 48

FIGURE 13 EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2020 (%) 54

FIGURE 14 WESTERN EUROPE IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY COUNTRY, 2020 (%) 55

FIGURE 15 ASIA-PACIFIC IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY COUNTRY, 2020 (%) 65

FIGURE 16 MIDDLE EAST & AFRICA IMMUNE THROMBOCYTOPENIA (ITP) MARKET BY REGION, 2020 (%) 73

FIGURE 17 COMPANY SHARE ANALYSIS: GLOBAL IMMUNE THROMBOCYTOPENIA (ITP) MARKET, 2020 (%) 78

Global Immune Thrombocytopenia (ITP) Market: Company Landscape:


Numerous players are operating in the Global Immune Thrombocytopenia market. Some of the big players have captured a significant share in the global immune thrombocytopenia market, taking advantage of their strong position and presence in the number of countries across the world. The top players in the global immune thrombocytopenia market are Novartis, Shire, and, Amgen, which hold a significant market share.


Novartis accounted for the major market share in 2017. The company has a diverse product portfolio in therapeutic areas including oncology, cardiology, ophthalmology, immunology, and dermatology. The market share is due to the company’s product Promacta which is used for treating chronic immune thrombocytopenia (ITP). The company is focused on launching the product in global markets. For instance, in April 2016, the company received the European Commission approval for Promacta/Revolade for the treatment of ITP. Additionally, the company has a distribution network globally and is focusing on strengthening its presence in untapped regions.


Shire is a prominent player in the Global Immune Thrombocytopenia market. Shire has a strong product portfolio in various therapeutic areas. The company has a strategy of entering in strategic collaborations to strengthen its market presence. For instance, in June 2016, Shire entered into a strategic partnership with Baxalta Incorporated (US). With this collaboration, the company strengthened the product portfolio of rare diseases. Additionally, the company has a strong distribution network in more than 100 countries with a strong presence in countries such as Ireland and the US.


Amgen is a renowned company in the market. The company focuses on research, development, and manufacture of innovative human therapeutic products. The company has a strategy of developing innovative medicines to meet unmet medical needs. The company’s products are available to patients in about 100 countries worldwide with strong market penetration in the US.


Apart from these companies, there are several other players in the market. The other players include CSL Limited, F. Hoffman Roche, Jiangsu Hengrui Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Rigel Pharmaceuticals, Inc., and Shionogi, Inc. Majority of these players have ITP treatment drugs in the pipeline.